Diabetic retinopathy: Treating systemic conditions aggressively can save sight

Cleveland Clinic Journal of Medicine

Volumn 72, Issue 5, 2005, Pages 447-454

  Sinclair, Stephen H ^a,b,e   Malamut, Richard ^b   Delvecchio, Cherie ^d   Li, Weiye ^a,c  

^a CROZER CHESTER MEDICAL CENTER   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c Division of Neurology   (United States)

^d PENNSYLVANIA COLLEGE OF OPTOMETRY   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ERYTHROPOIETIN; FLUDROCORTISONE; HEMOGLOBIN A1C; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRON; LIPID; MIDODRINE; PHENOTHIAZINE; PYRIDOSTIGMINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ANEMIA; CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; COMORBIDITY; COUGHING; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG CHOICE; DRUG COST; DRUG DOSE REGIMEN; EDEMA; FLUID INTAKE; HUMAN; HYPERCAPNIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOXEMIA; KIDNEY DISEASE; LIPID BLOOD LEVEL; ORTHOSTATIC HYPOTENSION; PROTEINURIA; REVIEW; SALT INTAKE; SEXUAL DYSFUNCTION; SLEEP APNEA SYNDROME; TACHYCARDIA; WHITE COAT HYPERTENSION;

EID: 20044379217     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.72.5.447     Document Type: Review

References (58)

1. Moss S, Klein R, Klein B. The 14-year incidence of visual loss in a diabetic population. The Wisconsin Epidemiological of Diabetic Retinopathy XVII. Ophthalmology 1998; 105:998-1003.
2. Klein R, Klein B. Vision disorders in diabetes. In: Group NDD, ed. Diabetes in America, 2nd ed. Bethesda, Md.: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease, 1995; v. NIH publication 95-1468.
3. Sinclair S, DelVecchio C. The internist's role in the management of diabetic retinopathy: screening for early detection. Cleve Clin J Med 2004; 71:151-159.
4. DCCT Research Group D. Color photography vs fluorescein angiography in the detection of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol 1987; 105:1344-1351.
5. DCCT Research Group. Diabetes Control and Complications Trial (DCCT): update. Diabetes Care 1990; 13:427-433.
6. United Kingdom Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes: UKPDS 34. Lancet 1998; 352:854-865.
7. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-853.
8. 1994 UNHaNESt. US National Health and Nutritional Examination Survey 1988 to 1994. Am J Prev Med 2002; 22:42-48.
9. Sinclair S. Macular retinal capillary hemodynamics in diabetic patients. Ophthalmology 1991; 98:1580-1586.
10. Grunwald J, Riva C, Brucker J, et al. Retinal blood flow in diabetes mellitus. Ophthalmology 1986; 93:590-595.
11. Sinclair S, Mainster M. Diabetic macular edema: new concepts of pathology and treatment. Semin Ophthalmol 1999; 14:197-199.
12. UKPDS group. UK Prospective Diabetes Study 38: tight blood pressure and risk of macrovascular and microvascular complications in type 2 diabetes. Br Med J 1998; 317:703-713.
13. Hansson L, Zanchetti A, Carruthers S, et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351:1755-1762.
14. Tuomilehto J, Rastenyte D, Birkenhager W, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension: Systolic Hypertension in Europe Trial. N Engl J Med 1999; 340:677-684.
15. Schrier R, Estacio R, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002; 61:1086-1097.
16. American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care 2002; 25(suppl 1):71-73.
17. Gillow J, Gibson J, Dodson P. Hypertension and diabetic retinopathy: what's the story? Br J Ophthalmol 1999; 83:1083-1087.
18. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145-153.
19. Arauz-Pacheco C, Parrott M, Raskin P. The treatment of hypertension in adult patients with diabetes. Diabetes Care 2002; 25:134-147.
20. Messerli F. Implications of discontinuation of doxazosin arm of ALLHAT: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Lancet 2000; 355:863-864.
21. Estacio RO, Schrier RW. Antihypertensive therapy in type 2 diabetes: implications of the appropriate blood pressure control in diabetes (ABCD) trial. Am J Cardiol 1998; 12:9R-14R.
22. Brenner B, Cooper M, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
23. Sinclair S, Stafford C, Sirgany B. A putative relation between obstructive sleep apnea and diabetic macular edema associated with nerve fiber layer infarcts. Arch Ophthalmol, (in press).
24. Sinclair S, DelVecchio C, Levin A. Treatment of anemia in the diabetic patient with retinopathy and kidney disease. Am J Ophthalmol 2003; 135:740-743.
25. Qiao Q, Keinanen-Kiukaanniemi S, Laara E. The relationship between hemoglobin levels and diabetic retinopathy. J Clin Epidemiol 1997; 50:153-158.
26. Davis MD, Fisher MR, Gangnon RE, et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Invest Ophthalmol Vis Sci 1998; 39:233-252.
27. Friedman E, L'Esperance F, Brown C, Berman D. Treating azotemia-induced anemia with erythropoietin improves diabetic eye disease. Kidney Int 2003; 87(suppl):57-63.
28. Bosman D, Winkler A, Marsden J, et al. Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care 2001; 24:495-499.
29. Inomata S, Itoh M, Imai H, Sato T. Serum levels of erythropoietin as a novel marker reflecting the severity of diabetic nephropathy. Nephron 1997; 75:426-430.
30. Jungers P, Choukroun G, Oualim Z, et al. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant 2001; 16:307-312.
31. Stevens L, Stigant C, Levin A. Should hemoglobin be normalized in patients with chronic kidney disease? Semin Dial 2002; 15:8-13.
32. Rossert J, McClellan WM, Roger SD, Verbeelen DL, Horl WH. Contribution of anaemia to progression of renal disease: a debate. Nephrol Dial Transplant 2002; 17(suppl 1):60-66.
33. Hayashi T, Suzuki A, Shoji T, et al. Cardiovascular effects of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 2000; 35:250-256.
34. Silverberg D, Wexler D, Sheps D, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001; 37:1775-1780.
35. Lopez Gomez J, Carrera F. What should the optimal target hemoglobin be? Kidney Int 2002; 61(suppl 80):39-43.
36. Muirhead N. A rationale for an individualized haemoglobin target. Nephrol Dial Transplant 2002; 17(suppl 1):2-7.
37. Keane WF. Lipids and progressive renal disease: the cardio-renal link. Am J Kidney Dis 1999; 34::xliii-xlvi.
38. Chew E, Klein M, Ferris III F, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Arch Ophthalmol 1996; 114:1079-1084.
39. Klein B, Moss S, Klein R, Surawicz T. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XIII. relationship of serum cholesterol to retinopathy and hard exudate. Ophthalmology 1991; 98:1261-1265.
40. Cusick M, Chew E, Chan C, Kruth HS, Murphy RP, Ferris FL 3rd. Histopathology and regression of retinal hard exudates in diabetic retinopthy after reduction of elevated serum lipid levels. Ophthalmology 2003; 110:2126-2133.
41. Stoohs R, Guilleminault C. Cardiovascular changes associated with obstructive sleep apnea. J Appl Physiol 1992; 72:582-589.
42. Hla KM, Young TB, Bidwetl T, et al. Sleep apnea and hypertension: a population-based study. Ann Intern Med 1994; 120:382-328.
43. Chaouat A, Weitzenblum E, Krieger J, et al. Pulmonary hemodynamics in the obstructive sleep apnea syndrome: results in 220 consecutive patients. Chest 1996; 109:380-386.
44. McNamara SG, Cistulli PA, Strohl KP, Sullivan CE. Clinical aspects of sleep apnea. In: Saunders NA, Sullivan CE, editors. Sleep and Breathing. 2nd ed. New York: Marcel Dekker, 1994:493-528.
45. Sajkov D, Cowie RJ, Thornton AT, et al. Pulmonary hypertension and hypoxemia in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 1994; 149:416-422.
46. Kushida CA, Efron B, Guilleminault C. A predictive morphometric model for obstructive sleep apnea syndrome. Ann Intern Med 1997; 127:581-587.
47. Sinclair SH, Grunwald JE, Riva CE, et al. Retinal vascular autoregulation in diabetes mellitus. Ophthalmology 1982; 98:748-750.
48. Grunwald JE, Riva CE, Brucker AJ, Sinclair SH, Petrig BL. Altered retinal vascular response to 100% oxygen breathing in diabetes mellitus. Ophthalmology 1984; 91:1447-1452.
49. Young T, Palta M, Dempsy J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing in middle-aged adults. N Engl J Med 1993; 328:1230-1235.
50. Guilleminault C, Tilkian A, Dement WC. The sleep apnea syndromes. Annu Rev Med 1976; 27:465-484.
51. Solberg Y, Rosner M, Belkin M. The association between cigarette smoking and ocular diseases. Surv Ophthalmol 1998; 42:535-547.
52. Morgado P, Chen H, Patel V, Herbert L, Kohner EM. The acute effect of smoking on retinal blood flow in subjects with and without diabetes. Ophthalmology 1994; 101:1220-1226.
53. Lyons T, Jenkins A, Zheng D, et al. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci 2004; 45:910-918.
54. Chung SM, Gay CA, McCrary JA 3rd. Nonarteritic ischemic optic neuropathy: the impact of tobacco use. Ophthalmology 1994; 101:779-782.
55. Moro F, Doro D, Mantovani E. Anterior ischemic optic neuropathy and aging. Metab Pediatr Syst Ophthalmol 1989; 12:46-57.
56. Mouton D, Gill A. Prevalence of diabetic retinopathy and evaluation of risk factors: a review of 1,005 diabetic clinic patients. S Afr Med J 1988; 74:399-402.
57. Sparrow J, McLeod B, Smith T, et al. The prevalence of diabetic retinopathy and maculopathy and their risk factors in the non-insulin-treated diabetic patients of an English town. Eye 1993; 7:158-163.
58. Moss S, Klein R, Klein B. Cigarette smoking and ten-year progression of diabetic retinopathy. Ophthalmology 1996; 103:1438-1442.